Navigation Links
Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Date:11/26/2012

SUNNYVALE, Calif., Nov. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, announced today, with the assistance of its Manhattan-based corporate counsel at JS Barkats, PLLC, it has initiated legal action to effect the expeditious cessation of trading and delisting of Amarantus common stock from the Berlin-Bremen Stock Exchange (the "BBSE"), and/or any other unofficially regulated markets controlled by the BBSE.

The BBSE is one of the few exchanges in the world that allows listing and trading to occur without the consent of the listed company. There is significant precedent under similar circumstances whereby many companies have been able to cease trading in their common stock on the BBSE. The Company recently became aware that its common stock was listed on the BBSE without the Company's prior knowledge, consent or authorization.  The Company did not authorize or direct any BBSE broker to act as a market maker for the Company's common stock.

"Unfortunately, the Berlin Stock Exchange allows any broker or shareholder to list a security; there is no need for company approval. Hence, the activity surrounding such listings is suspect and may be having a negative impact on trading activity on the Company's United States listing," said Sunny J. Barkats, Founding partner of JS Barkats.

The Company believes that it is in the best interests of its shareholders to ensure that any listing of the Company's common stock, whether in the US or on a foreign exchange, is sanctioned by the Company so that management is in a position to ensure regulatory compliance regarding regular trading and other trading-related activities with all United States securities laws. Cessatio
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
2. Amarantus BioSciences Wins MANF Patent Challenge in Europe
3. Amarantus BioSciences Issues CEO Letter to Shareholders
4. Amarantus BioSciences Secures $1.1 Million in Financing
5. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
8. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
9. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
10. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
11. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... XI,AN, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical ... and producer of plant extracts and pharmaceutical raw ... is pleased to,announce record sales and earnings for ... 2008., "In the first half of 2008, ...
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), a ... of novel drugs in the,therapeutic areas of infection, ... for the second quarter ended June 30, 2008., ... loss for the three months was $3.4 million ...
... 14 /PRNewswire-FirstCall/ - Ondine Biopharma,Corporation (the "Company" ... medical,technology company developing photodisinfection based products, today,announced ... ended June 30, 2008., "During the ... clinical,progress with our photodisinfection technology and we ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 3Advanced Life Sciences Announces Second Quarter 2008 Financial Results 4Advanced Life Sciences Announces Second Quarter 2008 Financial Results 5Advanced Life Sciences Announces Second Quarter 2008 Financial Results 6Advanced Life Sciences Announces Second Quarter 2008 Financial Results 7Advanced Life Sciences Announces Second Quarter 2008 Financial Results 8Advanced Life Sciences Announces Second Quarter 2008 Financial Results 9Advanced Life Sciences Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 2Ondine Biopharma Announces Second Quarter 2008 Financial Results 3Ondine Biopharma Announces Second Quarter 2008 Financial Results 4Ondine Biopharma Announces Second Quarter 2008 Financial Results 5Ondine Biopharma Announces Second Quarter 2008 Financial Results 6Ondine Biopharma Announces Second Quarter 2008 Financial Results 7Ondine Biopharma Announces Second Quarter 2008 Financial Results 8Ondine Biopharma Announces Second Quarter 2008 Financial Results 9Ondine Biopharma Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 11Ondine Biopharma Announces Second Quarter 2008 Financial Results 12Ondine Biopharma Announces Second Quarter 2008 Financial Results 13Ondine Biopharma Announces Second Quarter 2008 Financial Results 14Ondine Biopharma Announces Second Quarter 2008 Financial Results 15Ondine Biopharma Announces Second Quarter 2008 Financial Results 16Ondine Biopharma Announces Second Quarter 2008 Financial Results 17
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
(Date:7/9/2014)... high levels of vitamin D in their blood are more ... Patients with the highest levels of vitamin D have half ... levels, the findings reveal. , The study is the first ... cancer patients after their diagnosis which includes that produced ... with their long term survival prospects. , The ...
(Date:7/9/2014)... first make a copy of its DNA, a fundamental step ... times a day in the human body. While scientists have ... to replicate DNAthe enzymes that unzip the double-stranded DNA and ... how the process works. , Now, researchers at Rockefeller University ... on at the "replication fork"the point where DNA is split ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4
... studying the reliability of species distribution models for ... have focused their research on the endangered marsupial, ... Ecography demonstrates that studying weather events, rather ... a clearer insight into the Bettong,s movements, range ...
... BRUNSWICK, N.J. The National Institutes of Health (NIH) ... quick and economical analysis of tissue from breast cancer ... a common form of breast cancer is likely to ... minimize side effects. The NIH made its grant ...
... Large, persistent populations of genetically engineered canola ... North Dakota. As genetically engineered crops become increasingly ... potential ecological side effects. A study published ... reports that genetically engineered canola endowed with ...
Cached Biology News:Australia's endangered bettong reveals how weather effects species distribution 2Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments 2Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments 3